The Benefit of Repairing the Deltoid Ligament in Unstable Ankle Fractures

NCT06568276 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2025-08-13

No results posted yet for this study

Summary

Ankle fractures occur in 1 out of 800 persons a year and is a common injury. The deltoid ligament is necessary for the stability of the joint and guides choice of treatment. Cadaveric studies have shown that deltoid ligament repair gives more stability than the osteosynthesis of the lateral malleolus itself. The investigators want to show if suture of the deltoid ligament in unstable ankle fractures contribute to a better functional result and/or prevent long term osteoarthritis for our participants. Patients sustaining severe ankle fractures have shown a considerable loss of function that might affect their long term activities of daily living (ADL) function. Improving outcome for this group may preserve some patients' ability to work and reduce community expenses.

Conditions

  • Ankle Fractures
  • Deltoid Ligament; Sprain (Strain) (Ankle)

Interventions

PROCEDURE

Additional deep deltoid ligament suture

The deep deltoid ligament will be sutured through a curved incision lifting the tibialis posterior tendon out to be sutured back after tying the ligament to an anchor in the talus.

Sponsors & Collaborators

  • Sykehuset Innlandet HF

    collaborator OTHER
  • Helse Nord-Trøndelag HF

    collaborator OTHER
  • Helse-Bergen HF

    collaborator OTHER
  • Norwegian Institute of Public Health

    collaborator OTHER_GOV
  • Helse Stavanger HF

    collaborator OTHER_GOV
  • Trondheim University Hospital

    collaborator OTHER
  • Norwegian University of Science and Technology

    collaborator OTHER
  • Alesund Hospital

    collaborator OTHER
  • Nordlandssykehuset HF

    collaborator OTHER
  • Ostfold Hospital Trust

    lead OTHER

Principal Investigators

  • Frede Jon Frihagen, MD, PhD · Oestfold Hospital Trust

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-20
Primary Completion
2026-12-31
Completion
2032-07-01

Countries

  • Norway

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06568276 on ClinicalTrials.gov